Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP526666.RAdple7bNzHJ580-K53l4kTpPTQ4IUdZTu_xs9AckIBGE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP526666.RAdple7bNzHJ580-K53l4kTpPTQ4IUdZTu_xs9AckIBGE130_assertion type Assertion NP526666.RAdple7bNzHJ580-K53l4kTpPTQ4IUdZTu_xs9AckIBGE130_head.
- NP526666.RAdple7bNzHJ580-K53l4kTpPTQ4IUdZTu_xs9AckIBGE130_assertion description "[In the past, few treatment options were available; however, several new therapies with proven efficacy have recently become available to treat and prevent HAE attacks, such as plasma-derived and recombinant C1-INHs that replace the deficient protein, bradykinin receptor antagonist (icatibant) that blocks bradykinin activity and kallikrein inhibitor (ecallantide) that prevents bradykinin release.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526666.RAdple7bNzHJ580-K53l4kTpPTQ4IUdZTu_xs9AckIBGE130_provenance.
- NP526666.RAdple7bNzHJ580-K53l4kTpPTQ4IUdZTu_xs9AckIBGE130_assertion evidence source_evidence_literature NP526666.RAdple7bNzHJ580-K53l4kTpPTQ4IUdZTu_xs9AckIBGE130_provenance.
- NP526666.RAdple7bNzHJ580-K53l4kTpPTQ4IUdZTu_xs9AckIBGE130_assertion SIO_000772 23634741 NP526666.RAdple7bNzHJ580-K53l4kTpPTQ4IUdZTu_xs9AckIBGE130_provenance.
- NP526666.RAdple7bNzHJ580-K53l4kTpPTQ4IUdZTu_xs9AckIBGE130_assertion wasDerivedFrom befree-20150227 NP526666.RAdple7bNzHJ580-K53l4kTpPTQ4IUdZTu_xs9AckIBGE130_provenance.
- NP526666.RAdple7bNzHJ580-K53l4kTpPTQ4IUdZTu_xs9AckIBGE130_assertion wasGeneratedBy ECO_0000203 NP526666.RAdple7bNzHJ580-K53l4kTpPTQ4IUdZTu_xs9AckIBGE130_provenance.